Baird Downgrades Ra Pharma (RARX) to Neutral Following Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ra Pharmaceuticals (RARX) Could Draw a Higher Bid - RBC
October 10, 2019 10:39 AM EDTRBC Capital analyst Kennen MacKay weighed in on news that Ra Pharmaceuticals (NASDAQ: RARX) agreed to be acquired by UCB for $48/share. The analyst said the price should be higher and sees the potential for competitive bids/interest.
MacKay calls the bid... More
